Can NK cells play a role in anti-CD20 immunotherapy for CLL patients?

被引：0
|
作者：
Le Garff-Tavemier, Magali [1 ]
De Romeuf, Christophe [2 ]
Teillaud, Jean-Luc [3 ]
Decocq, Julie [2 ]
Dutertre, Charles-Antoine [3 ]
Debre, Patrice [1 ]
Merle-Beral, Helene [1 ]
Vieillard, Vincent [1 ]
机构：
[1] Hop La Pitie Salpetriere, INSERM, U543, Paris, France
[2] Lab Francais Fractionnement & Biotechnol, Les Ulis, France
[3] Ctr Rech Biomed Cordeliers, Paris, France
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.3103.3103
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3103
引用
收藏
页码：913A / 913A
页数：1
相关论文
共 50 条
  • [1] Is there a role for anti-CD20 antibodies in CLL?
    Shah, Harsh R.
    Stephens, Deborah M.
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2021, (01) : 68 - 75
  • [2] Immunotherapy with anti-CD20 compounds
    von Schilling, C
    [J]. SEMINARS IN CANCER BIOLOGY, 2003, 13 (03) : 211 - 222
  • [3] BLOCKING B-CELLS (ANTI-CD20/ANTI-CD20)
    Isenberg, David A.
    [J]. RHEUMATOLOGY, 2015, 54 : 1 - 1
  • [4] Association between nk cells and response to anti-cd20 medications in multiple sclerosis patients
    Casanova Peno, Ignacio
    Dominguez Mozo, Maria Inmaculada
    Garcia-Martinez, Maria Angel
    de la Cuesta, David
    Abellan, Sara
    Donas Jimenez, Maria Teresa Garcia
    Rius Hernandez, Irina
    Minano, Elena
    Lopez-Ruiz, Pedro
    Arroyo, Rafael
    Alvarez-Lafuente, Roberto
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 904 - 905
  • [5] Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies
    M Le Garff-Tavernier
    J Decocq
    C de Romeuf
    C Parizot
    C A Dutertre
    E Chapiro
    F Davi
    P Debré
    J F Prost
    J L Teillaud
    H Merle-Beral
    V Vieillard
    [J]. Leukemia, 2011, 25 : 101 - 109
  • [6] Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies
    Le Garff-Tavernier, M.
    Decocq, J.
    de Romeuf, C.
    Parizot, C.
    Dutertre, C. A.
    Chapiro, E.
    Davi, F.
    Debre, P.
    Prost, J. F.
    Teillaud, J. L.
    Merle-Beral, H.
    Vieillard, V.
    [J]. LEUKEMIA, 2011, 25 (01) : 101 - 109
  • [7] Should Venetoclax Be Used With or Without Anti-CD20 Therapy for CLL?
    Furman, Richard R.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 209 - 211
  • [8] Monitoring and Treatment of Patients Undergoing Immunotherapy With Anti-CD20 Who are Exposed to HBV
    Seto, Wai-Kay
    Chan, Thomas Sau-Yan
    Hwang, Yu-Yan
    Mak, Lung-Yi
    Wong, Danny Ka-Ho
    Fung, James
    Liu, Kevin Sze-Hang
    Cheung, Ka-Shing
    Lai, Ching-Lung
    Kwong, Yok-Lam
    Yuen, Man-Fung
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (07) : 1410 - 1412
  • [9] BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naive elderly patients with CLL
    Rogers, Andrew
    Woyach, Jennifer A.
    [J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [10] HDAC6 INHIBITION SENSITIZES TUMOR CELLS TO ANTI-CD20 IMMUNOTHERAPY IN VIVO
    Bobrowicz, M.
    Dwojak, M.
    Stachura, J.
    Angelika, M.
    Beata, P.
    Marta, S.
    Miazek, N.
    Zapala, P.
    Golab, J.
    Winiarska, M.
    [J]. HAEMATOLOGICA, 2017, 102 : 568 - 568
12345